Berlin, Germany - Vara announced today it received a new CE certificate for its new breast-imaging AI – the only on the market allowed to operate as an independent second reader for both screening and diagnostic use. It marks the company’s entry into the European market.

This milestone comes at a critical moment. National screening programs in Europe face mounting radiologist shortages, as well as aging populations and expanded age ranges that demand even more expert time. Vara’s CE mark affirms the safety and clinical evidence for AI as a second reader.

Beyond screening, Vara’s independent read delivers immediate value for providers particularly indiagnostic workflows where maintaining a human second read is often not economically feasible.

The CE-marked product is available in Europe starting today, as an independent second read or decision support system including analysis of mammograms from prior screening rounds. Providers can integrate Vara directly in their PACS viewer or via the Vara platform – the latter of which currently serves 40% of the German national screening program.

Nature Medicine’s publication of the landmark PRAIM study – initiated by Vara – earlier this year made the company’s pioneering efforts as an independent reader possible. PRAIM is the world’s largest prospective, real-world study of AI in healthcare: 460,000 women enrolled across Germany, demonstrating statistically significant superiority in cancer detection rate and meaningful workload reduction for radiologists.

In approving Vara's AI for independent second reading, regulators also recognized Vara’s autonomous, prospective AI monitoring, which is setting a new standard for responsible, real-time quality assurance.

“Our ambition has always been to pioneer data-driven AI at a nationwide scale,” said Stefan Bunk, co-founder and CTO of Vara. “The industry has long moved beyond retrospective evidence. Now, by pairing population-wide, real-world results with automatic real-time monitoring, we’re offering a credible, scalable path for AI as an independent reader – and we’re grateful the regulator acknowledged this approach.”

About Vara

Vara builds AI and cloud workflow tools for breast imaging, helping radiologists detect cancer earlier while reducing unnecessary recalls and reading time. In Germany’s national screening program, Vara supports ~40% of screening centers, processing ~150,000 mammograms monthly and >1.5 million annually. PRAIM – with 460,000 participants, 12 centers, and no exclusioncriteria – was published in Nature Medicine (2025) and is the largest prospective real-world study of AI in healthcare – press@vara.ai

About Vi Partners
Vi Partners is the longest-established Swiss Venture Capital firm. For more than 20 years, Vi Partners has been supporting innovative Technology and Healthcare companies, investing CHF 350m in 73 startups. Vi Partners-managed funds are backed by Switzerland’s most visible companies and institutions, including ETH Zurich, ABB, Bühler, UBS, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva and ZKB as well as the European Investment Fund and many other institutional investors. Learn more on: www.vipartners.ch